In Jordanian samples of CRC patients, wild-type KRAS was seen in 57% of patients, while 43% were KRAS mutant and showed significantly worse survival outcomes (HR = 2.045 [1.3-3.2]) compared to wild-type KRAS [22]. Here, KRAS is linked to colorectal carcinoma.